American College of Physicians recommends monotherapy with cognitive therapy or second-generation antidepressant for patients in acute phase of moderate-to-severe depression
Your search for major depressive disorder returned 113 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Investigators from the Veteran’s Affairs Center for Innovation to Implementation and Stanford University searched publication databases through June 2022 for observational studies about methamphetamine-associated heart failure.
Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.
Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.
The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.
Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.
Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.
The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Adults with major depressive disorder and a history of childhood trauma can still benefit from recommended depression treatments.
HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.
Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.
The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.
For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.
Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.